News | June 18, 2022
Stelis Biopharma’s two biologics manufacturing facilities receive EU cGMP accreditation
Both manufacturing facilities are based out of Benguluru, India
Both manufacturing facilities are based out of Benguluru, India
Revenues from operations for the full year ended March 31, 2022 stood at Rs. 590.05 crore as compared to Rs. 449.82 crore in FY21
Expanding diagnostics footprint in East India
Apollo Hospitals Chennai is the first healthcare institution in South India to use this protected TAVI / TAVR technology.
Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
48% of people are either hypertensive or at risk of becoming hypertensive & 30% of people have a high Waist Hip Ratio (WHR) – an early indication of the onset of CVDs
Site has a capital investment program of ~$30 million spent or committed over the last three years to expand capabilities and improve operational efficiencies
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
The proposed combination involves corporate restructuring of JVCO, including through acquisition by Haleon via demerger
The Ayushman Bharat Digital Mission (ABDM) aims to replicate this success in healthcare delivery by building an equitable, accessible and inclusive ecosystem
Subscribe To Our Newsletter & Stay Updated
